Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients

Liu, David; Schilling, B.; Liu, Derek; Sucker, A.; Livingstone, E.; Jerby-Arnon, Livnat; Zimmer, L.; Gutzmer, R.; Satzger, I.; Loquai, C.; Grabbe, S.; Vokes, N.; A. Margolis, Claire; Conway, J.; X. He, M.; A. Elmarakeby, Haitham; Dietlein, Felix; Miao, Diana; Tracy, A.; Gogas, H.; Goldinger, S.; Utikal, J.; Blank, C.; Rauschenberg, R.; von Bubnoff, D.; Krackhardt, A.; Weide, B.; Haferkamp, S.; Kiecker, F.; Izar, B.; Garraway, L.; Regev, A.; Flaherty, K.; Paschen, A.; V. Van Allen, E.; Schadendorf, D.

doi:10.1038/s41591-019-0654-5

Public

Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients

Shared by NobleBlocks on Dec 1, 2019 • 12:00 AM UTC

Authors:

David Liu

B. Schilling

Derek Liu

Abstract

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome an...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!